Genetically Engineered Mouse Models of Pancreatic Cancer
- 1 November 2012
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in The Cancer Journal
- Vol. 18 (6), 502-510
- https://doi.org/10.1097/ppo.0b013e31827ab4c4
Abstract
Pancreatic ductal adenocarcinoma is the 10th most common cancer and the fourth leading cause of cancer-related death in the United States. Despite great effort, the prognosis for patients with this disease remains dismal with a 5-year survival rate of just 4% to 6%. Although several important advances have improved our understanding of the underlying biology of pancreatic cancer, this knowledge has not translated into novel therapeutic approaches and effective systemic or targeted therapies. Pancreatic cancer is one of the malignancies most difficult to treat, with remarkable intrinsic resistance to both standard and targeted chemotherapy as well as ionizing radiation. Surgical intervention remains the only potentially curative approach. However, most patients present with inoperable and/or metastatic disease and are therefore excluded from surgery. Accordingly, new therapeutic options are desperately needed. In vivo models to study innovative and alternative treatment approaches are of major importance. A variety of genetically engineered mouse models of pancreatic cancer have been developed over the last decade. However, these models display different characteristics, and not all of them are suited for preclinical studies. In this review, we aim to review the mouse models available, their experimental use, their clinical relevance and limitations, and future directions.Keywords
This publication has 93 references indexed in Scilit:
- Changes in Connexin43 Expression and Localization During Pancreatic Cancer ProgressionThe Journal of Membrane Biology, 2012
- Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic CancerCancer Cell, 2012
- The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinomaNature, 2012
- Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose MetabolismCell, 2012
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal AdenocarcinomaCancer Cell, 2012
- Ongoing Notch signaling maintains phenotypic fidelity in the adult exocrine pancreasDevelopmental Biology, 2012
- RETRACTED: Notch-1 induces epithelial–mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cellsCancer Letters, 2011
- Stem cells in gastroenterology and hepatologyNature Reviews Gastroenterology & Hepatology, 2009
- Context-Dependent Transformation of Adult Pancreatic Cells by Oncogenic K-RasCancer Cell, 2009
- Chronic Pancreatitis Is Essential for Induction of Pancreatic Ductal Adenocarcinoma by K-Ras Oncogenes in Adult MiceCancer Cell, 2007